Peptide Atlas · Peptide

Goserelin

Goserelin is a GnRH agonist analogue that reduces testosterone secretion; in a randomized trial in 415 men with locally advanced prostate cancer, adding three years of goserelin to radiotherapy raised five-year survival from 62% to 79%.

established

provisional
PubChem 5311128
2 citations
0 discussions
0 followers
D-Ser(tBu)6-AzaGly10-LHRH
Goserelin acetate
Zoladex

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- established
  Claim: Goserelin during chemotherapy reduced ovarian failure in breast cancer (POEMS RCT) standing
- resolved
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS, POEMS/S0230 Investigators
pmid 25738668
- established
  Claim: Radiotherapy plus goserelin improved survival in locally advanced prostate cancer (RCT) standing
- resolved
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M
pmid 9233866

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.